 This research has identified two distinct subtypes of acute myeloid leukemia, AML, one with a poor prognosis, and another with intermediate risk. The former is characterized by high levels of .1L phosphorylation, oxygen expression, and CDK1 activity, as well as increased phosphorylation of proteins involved in RNA metabolism, replication, and DNA damage. This subtype is also highly sensitive to several types of drugs, including genotoxic agents and inhibitors of mitotic kinases and inosine, 5-foot monophosphate dehydrogenase, IMPDH. The latter is characterized by lower levels of all of these factors, and is more likely to respond to treatment. The authors suggest that these findings could lead to the development of targeted therapies for AML patients with poor prognosis. This article was authored by Pedro Casado, Ana Rio Machin, Juho J. Mitenen, and others.